8:30 am
Registration and Morning Networking

9:00 am Chairperson’s Opening Remarks

OPTIMIZING THE ROLE OF MEDICAL AFFAIRS IN IMPROVING MARKET ACCESS

9:10 am The Role of Medical Managed Care Teams in Educating Payers on the Value of Gene Therapies to Support Optimal Patient Access

Synopsis

  • Discover how Medical Managed Care Teams are engaging and educating cross-functional payer teams on gene therapy topics
  • Discover how KOL’s are being engaged and educated to support payer interactions
  • Assess the key steps to engaging early adopters and building therapeutic advocates within KOL and payer communities
  • Understand how KOL and payer insights are being gathered and relayed to Market Access teams to ensure realistic and viable proposals are being delivered

9:40 am Demonstrate Value and Achieve Optimal Access to Gene Therapy via a Patient-Centric Approach

  • Nick Li Senior Director Market Access Lead, uniQure

Synopsis

As gene therapies create a paradigm shift in the reimbursement landscape, uncover the advanced health economic modelling and the cross functional
collaborations between health economists, clinicians, patient and patient advocacy groups, and gene therapy developers to demonstrate the value and achieve optimal access via a patient-centric approach

10:10 am
Morning Coffee Break

10:40 am European Spotlight: Identify How European Gene Therapy Leaders Have Engaged Local KOL’s To Support Navigating the Stringent Reimbursement Landscape

  • Inha Kim Executive Director, Medical Affairs, Northern Europe, PTC Therapeutics

Synopsis

This case study will provide insights into the lessons learned when seeking market access in a European patient landscape We will review some of the critical differences in healthcare system structures and country specific incentives to manage uncertainties around long-term product value

MAXIMIZING THE VALUE OF MEDICAL AFFAIRS WHEN ENGAGING IN CROSS-FUNCTIONAL COLLABORATIONS

11:10 am Panel Discussion: What Is the Role of Medical Affairs in the Launch of a Gene Therapy

Synopsis

  • How can medical affairs prepare the market for an imminent launch beyond reactive responses?
  • How should medical affairs promote the distinctive features of a clinical program?
  • How do you keep KOL’s engaged and the gene therapy front of mind in a complaint manner?

12:00 pm
Lunch & Networking

DEFINING THE VALUE OF MEDICAL AFFAIRS WHEN ENGAGING IN CROSS-FUNCTIONAL COLLABORATIONS

1:30 pm Field Medical Value Throughout the Drug Lifecycle

Synopsis

  • Discover how Medical Affairs teams are working collaboratively with Clinical Development teams and the approaches being adopted to define clear definition of roles that mitigate a historic ‘territorial’ nature
  • Understand the steps taken to create partnerships with Clinical Operations and Development teams and assess examples of positive working dynamics
  • Learn how best to demonstrate the access Medical Affairs can provide to Clinical teams
  • Identify how platforms are being built to monetize Medical Affairs outputs to successfully demonstrate value

ENHANCING THE VALUE OF MEDICAL AFFAIRS IN A LAUNCH ENVIRONMENT

2:20 pm Best Practices to Creating a Medical Affairs Plan from Scratch that Provides the Foundation for a Successful Gene Therapy Launch Plan

  • Fatima Ahmad Vice President, Medical Affairs, Castle Creek Biosciences

Synopsis

  • Identify the key steps to building a medical affairs plan that is specific to support gene therapy launches
  • Discuss how medical affairs functions are defining the roadmap and the strategic considerations to ensure the plan is future proof

2:50 pm
Afternoon Break & Networking

3:30 pm Uncover How To Demonstrate The Incremental Value of Gene Therapies in a Space Where Other Treatment Options Exist and There Is a Perception of Little Unmet Need

Synopsis

  • Identify how gene therapy developers are disrupting therapeutic areas such as Hemophilia, where non gene therapy treatment options exist and are currently valued
  • Discuss how adopting a co-creation model with physicians and patient advocacy groups increases ‘buy in’ and strengthens the value story

4:00 pm Gene Therapy University: Explore the Innovative Formats Being Leveraged to Ensure Continuous Medical Education and Engagement

  • Deborah Marsden Global Medical Expert, Genetic/ Metabolic Disorders, Medical Affairs, Ultragenyx

Synopsis

  • Identify how Medical Affairs Functions are leading on initiatives that support with providing accessible and complimentary information on demand
  • Assess the importance of providing ‘bitesize’ information that factors in physician capacity to provide educational resources that support realistic use

4:30 pm Chairs Closing Remarks

4:40 pm End of Conference